Paper32059151
MLL1 combined with GSK3 and MAP2K inhibition improves the development of in vitro-fertilized embryos.
Han X and 9 others. Theriogenology, 2020. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. MLL1 combined with GSK3 and MAP2K inhibition improves the development of in vitro-fertilized embryos. Papers, record 32059151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32059151
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- MLL1 combined with GSK3 and MAP2K inhibition improves the development of in vitro-fertilized embryos.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cattle | Major topic |
| Fertilization in Vitro | Major topic |
| Glycogen Synthase Kinase 3 | Major topic |
| Histone-Lysine N-Methyltransferase | Major topic |
| Mitogen-Activated Protein Kinase Kinases | Major topic |
| Myeloid-Lymphoid Leukemia Protein | Major topic |
| Animals | |
| Embryo Culture Techniques | |
| Female | |
| Gene Expression Regulation, Developmental | |
| Kruppel-Like Factor 4 |
Source PubMed
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41379212 | Silencing KMT2A with siRNA induces apoptosis and cell cycle arrest in high-grade serous ovarian carcinoma cells by modulating GOF p53-dependent pathways, highlighting its potential as a therapeutic target. | Med Oncol | 2025 | https://conductscience.org/library/papers/41379212 | PubMed |
| 38202281 | WD Repeat Domain 5 Inhibitors for Cancer Therapy: Not What You Think. | J Clin Med | 2024 | https://conductscience.org/library/papers/38202281 | PubMed |
| 37708089 | A novel TOX3-WDR5-ABCG2 signaling axis regulates the progression of colorectal cancer by accelerating stem-like traits and chemoresistance. | PLoS Biol | 2023 | https://conductscience.org/library/papers/37708089 | PubMed |
| 37569280 | Mixed-Lineage Leukemia 1 Inhibition Enhances the Differentiation Potential of Bovine Embryonic Stem Cells by Increasing H3K4 Mono-Methylation at Active Promoters. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37569280 | PubMed |
| 37031197 | KLF4 transcription factor in tumorigenesis. | Cell Death Discov | 2023 | https://conductscience.org/library/papers/37031197 | PubMed |
| 36847888 | The adaptation of bovine embryonic stem cells to the changes of feeder layers. | In Vitro Cell Dev Biol Anim | 2023 | https://conductscience.org/library/papers/36847888 | PubMed |
| 35454256 | Pluripotent Core in Bovine Embryos: A Review. | Animals (Basel) | 2022 | https://conductscience.org/library/papers/35454256 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32059151
GET https://conductscience.org/api/papers/v1/32059151/authors